169 related articles for article (PubMed ID: 38783159)
1. Increased coexpression of PD-L1 and IDO1 is associated with poor overall survival in patients with NK/T-cell lymphoma.
Li Y; Chen K; Chen B; Zeng R; He Y; Wang C; Zhong M; Liu X; Chen X; Xiao L; Zhou H
Leukemia; 2024 Jul; 38(7):1553-1563. PubMed ID: 38783159
[TBL] [Abstract][Full Text] [Related]
2. Co-expression of IDO1 and PD-L1 in lung squamous cell carcinoma: Potential targets of novel combination therapy.
Takada K; Kohashi K; Shimokawa M; Haro A; Osoegawa A; Tagawa T; Seto T; Oda Y; Maehara Y
Lung Cancer; 2019 Feb; 128():26-32. PubMed ID: 30642449
[TBL] [Abstract][Full Text] [Related]
3. Programmed death ligand 1/indoleamine 2,3-dioxygenase 1 expression and tumor-infiltrating lymphocyte status in renal cell carcinoma with sarcomatoid changes and rhabdoid features.
Kiyozawa D; Takamatsu D; Kohashi K; Kinoshita F; Ishihara S; Toda Y; Eto M; Oda Y
Hum Pathol; 2020 Jul; 101():31-39. PubMed ID: 32360490
[TBL] [Abstract][Full Text] [Related]
4. Programmed Cell Death 1 and Programmed Cell Death Ligands in Extranodal Natural Killer/T Cell Lymphoma: Expression Pattern and Potential Prognostic Relevance.
Muhamad H; Suksawai N; Assanasen T; Polprasert C; Bunworasate U; Wudhikarn K
Acta Haematol; 2020; 143(1):78-88. PubMed ID: 31330525
[TBL] [Abstract][Full Text] [Related]
5. Indoleamine 2,3-dioxygenase 1 and programmed cell death-ligand 1 co-expression correlates with aggressive features in lung adenocarcinoma.
Kozuma Y; Takada K; Toyokawa G; Kohashi K; Shimokawa M; Hirai F; Tagawa T; Okamoto T; Oda Y; Maehara Y
Eur J Cancer; 2018 Sep; 101():20-29. PubMed ID: 30014971
[TBL] [Abstract][Full Text] [Related]
6. Programmed death-ligand 1 and its soluble form are highly expressed in nasal natural killer/T-cell lymphoma: a potential rationale for immunotherapy.
Nagato T; Ohkuri T; Ohara K; Hirata Y; Kishibe K; Komabayashi Y; Ueda S; Takahara M; Kumai T; Ishibashi K; Kosaka A; Aoki N; Oikawa K; Uno Y; Akiyama N; Sado M; Takei H; Celis E; Harabuchi Y; Kobayashi H
Cancer Immunol Immunother; 2017 Jul; 66(7):877-890. PubMed ID: 28349165
[TBL] [Abstract][Full Text] [Related]
7. The expression and clinical significance of programmed cell death receptor 1 and its ligand in tumor tissues of patients with extranodal nasal NK/T cell lymphoma.
Feng Y; Feng X; Jing C; Yu X; Zheng Y; Xu C
Sci Rep; 2022 Jan; 12(1):36. PubMed ID: 34996890
[TBL] [Abstract][Full Text] [Related]
8. PD-L1 and IDO1 expression and tumor-infiltrating lymphocytes in osteosarcoma patients: comparative study of primary and metastatic lesions.
Toda Y; Kohashi K; Yamada Y; Yoshimoto M; Ishihara S; Ito Y; Iwasaki T; Yamamoto H; Matsumoto Y; Nakashima Y; Mawatari M; Oda Y
J Cancer Res Clin Oncol; 2020 Oct; 146(10):2607-2620. PubMed ID: 32388585
[TBL] [Abstract][Full Text] [Related]
9. Up-regulation of indoleamine 2,3-dioxygenase 1 (IDO1) expression and catalytic activity is associated with immunosuppression and poor prognosis in penile squamous cell carcinoma patients.
Zhou QH; Han H; Lu JB; Liu TY; Huang KB; Deng CZ; Li ZS; Chen JP; Yao K; Qin ZK; Liu ZW; Li YH; Guo SJ; Ye YL; Zhou FJ; Liu RY
Cancer Commun (Lond); 2020 Jan; 40(1):3-15. PubMed ID: 32125093
[TBL] [Abstract][Full Text] [Related]
10. Identification of an IDO1-based immune classifier for survival prediction of upper tract urothelial carcinoma.
Zhong W; Yang M; Cheng S; Hou W; Wang B; Chen J; Yu H; Ouyang Y; Wang X; Ou Z; Xu P; Li X; Zhou L; Huang J; Wang C; Lin T
Cancer Sci; 2022 Mar; 113(3):852-863. PubMed ID: 34962030
[TBL] [Abstract][Full Text] [Related]
11. Expression of Tryptophan Metabolism Enzymes in Patients with Diffuse Large B-cell Lymphoma and NK/T-cell Lymphoma.
Guo D; Wang Y; Wu X; Gao Y; Wang A; Zhang Z; Zhao K; Wang X; Liu M; Zhang Y; Li M; Chen R; Sun J; Zhang Y
Cancer Med; 2023 Jun; 12(11):12139-12148. PubMed ID: 37148546
[TBL] [Abstract][Full Text] [Related]
12. Immune checkpoints indoleamine 2,3-dioxygenase 1 and programmed death-ligand 1 in oral mucosal dysplasia.
Sieviläinen M; Passador-Santos F; Almahmoudi R; Christopher S; Siponen M; Toppila-Salmi S; Salo T; Al-Samadi A
J Oral Pathol Med; 2018 Sep; 47(8):773-780. PubMed ID: 29851145
[TBL] [Abstract][Full Text] [Related]
13. PD-L1 and IDO1 Are Expressed in Poorly Differentiated Thyroid Carcinoma.
Rosenbaum MW; Gigliotti BJ; Pai SI; Parangi S; Wachtel H; Mino-Kenudson M; Gunda V; Faquin WC
Endocr Pathol; 2018 Mar; 29(1):59-67. PubMed ID: 29372535
[TBL] [Abstract][Full Text] [Related]
14. Expression of programmed cell death ligand 1 (PD-L1) in advanced stage EBV-associated extranodal NK/T cell lymphoma is associated with better prognosis.
Kim WY; Jung HY; Nam SJ; Kim TM; Heo DS; Kim CW; Jeon YK
Virchows Arch; 2016 Nov; 469(5):581-590. PubMed ID: 27595782
[TBL] [Abstract][Full Text] [Related]
15. [Expression of pSTAT3 and PD-L1 in extranodal NK/T cell lymphoma and its clinical significance].
Zhang F; Luo DL; Chen Y; Yan JH; Luo LQ; Liu J; Liu YH
Zhonghua Bing Li Xue Za Zhi; 2020 Oct; 49(10):999-1002. PubMed ID: 32992412
[No Abstract] [Full Text] [Related]
16. The correlation of clinicopathological features and prognosis in extranodal natural killer/T cell lymphoma: a report of 42 cases in the early stage.
Zeng L; Huang W; Cao Z; Zheng B; Liu X; Guo L; Feng X
Ann Hematol; 2019 Jun; 98(6):1467-1476. PubMed ID: 30895352
[TBL] [Abstract][Full Text] [Related]
17. PD-L1 is upregulated by EBV-driven LMP1 through NF-κB pathway and correlates with poor prognosis in natural killer/T-cell lymphoma.
Bi XW; Wang H; Zhang WW; Wang JH; Liu WJ; Xia ZJ; Huang HQ; Jiang WQ; Zhang YJ; Wang L
J Hematol Oncol; 2016 Oct; 9(1):109. PubMed ID: 27737703
[TBL] [Abstract][Full Text] [Related]
18. Indoleamine 2,3-Dioxygenase 2 Immunohistochemical Expression in Resected Human Non-small Cell Lung Cancer: A Potential New Prognostic Tool.
Mandarano M; Bellezza G; Belladonna ML; Vannucci J; Gili A; Ferri I; Lupi C; Ludovini V; Falabella G; Metro G; Mondanelli G; Chiari R; Cagini L; Stracci F; Roila F; Puma F; Volpi C; Sidoni A
Front Immunol; 2020; 11():839. PubMed ID: 32536910
[TBL] [Abstract][Full Text] [Related]
19. Predicting treatment response of patients with extranodal natural killer/T-cell lymphoma based on levels of PD-L1 mRNA and soluble PD-L1.
Feng Y; Jing C; Yu X; Cao X; Xu C
Hematol Oncol; 2020 Oct; 38(4):467-477. PubMed ID: 32515093
[TBL] [Abstract][Full Text] [Related]
20. Differential expression of PD-L1 and IDO1 in association with the immune microenvironment in resected lung adenocarcinomas.
Zhang ML; Kem M; Mooradian MJ; Eliane JP; Huynh TG; Iafrate AJ; Gainor JF; Mino-Kenudson M
Mod Pathol; 2019 Apr; 32(4):511-523. PubMed ID: 30367104
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
